Drug

Camostat

In clinical development

Emerging researchLate-stage development

Also known as Camostatum.

RxNorm53141 ChEMBLCHEMBL590799UNII0FD207WKDU

Research papers

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Clinical trial2024-08-02Results posted · ClinicalTrials.gov

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.

Research2023-10-01Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19

Clinical trial2023-06-28Results posted · ClinicalTrials.gov

The DAWN Antivirals Trial: the Efficacy of Antivirals for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial

Clinical trial2022-07-13Terminated · ClinicalTrials.gov

The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden

Clinical trial2022-07-12Terminated · ClinicalTrials.gov

Clinical trial2022-03-04Terminated · ClinicalTrials.gov

A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.

Clinical trial2022-03-03Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Camostat

Aliases & brands

Camostatum

RxNorm CUI

53141

ChEMBL ID

CHEMBL590799

UNII

0FD207WKDU

Clinical trials

6 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2023

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 6

Phase 24Phase 2 / 31Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

CompletedPH II/IIIKey trialNational Institute of Allergy and Infectious Diseases (NIAID)n=4,0442023

The DAWN Antivirals Trial: the Efficacy of Antivirals for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial

TerminatedPH IIIKU Leuvenn=442022

Recent completions

Trials that read out recently, adding to the completed evidence base.

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

CompletedPH II/IIIKey trialNational Institute of Allergy and Infectious Diseases (NIAID)n=4,0442023

CompletedPH IIStanford Universityn=1222023

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023 · 17 cites